Abstract
OBJECTIVES To identify any associations between in utero exposure to five over-the-counter (non-prescription) analgesics (paracetamol, ibuprofen, aspirin, diclofenac, naproxen) and adverse neonatal outcomes.
DESIGN Retrospective cohort study using the Aberdeen Maternity and Neonatal Databank.
PARTICIPANTS 151,141 singleton pregnancies between 1985 and 2015.
MAIN OUTCOME MEASURES Premature delivery (<37 weeks), stillbirth, neonatal death, birthweight, standardised birthweight score, neonatal unit admission, APGAR score at 1 and 5 minutes, neural tube and amniotic band defects, gastroschisis and, in males, cryptorchidism, and hypospadias.
RESULTS 83.7% of women taking over-the-counter analgesics reported first trimester use when specifically asked about use at their first antenatal clinic visit. Pregnancies exposed to at least one of the five analgesics were significantly independently associated with increased risks for premature delivery <37 weeks (aOR=1.50, 95%CI 1.43-1.58), stillbirth (aOR=1.33, 95%CI 1.15-1.54), neonatal death (aOR=1.56, 95%CI 1.27-1.93), birthweight <2,500g (aOR=1.28, 95%CI 1.20-1.37), birthweight >4,000g (aOR=1.09, 95%CI 1.05-1.13), admission to neonatal unit (aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at 1 minute (aOR=1.18, 95%CI 1.13-1.23) and 5 minutes (aOR=1.48, 95%CI 1.35-1.62), neural tube defects (aOR=1.64, 95%CI 1.08-2.47) and hypospadias (aOR=1.27, 95%CI 1.05-1.54 males only). The overall prevalence of over-the-counter analgesics use during pregnancy was 29.1%, however it rapidly increased over the 30-year study period, to include over 60% of women in the last seven years of the study. This makes our findings highly relevant to the wider pregnant population.
CONCLUSIONS Over-the-counter (non-prescription) analgesics consumption during pregnancy was associated with a substantially higher risk for adverse perinatal health outcomes in the offspring. The use of paracetamol in combination with other non-steroidal anti-inflammatory drugs conferred the highest risk. The increased risks of adverse neonatal outcomes associated with non-prescribed, over-the-counter, analgesics use during pregnancy indicate that healthcare guidance for pregnant women regarding analgesic use need urgent updating.
Funding Biotechnology and Biological Sciences Research council (BBSRC) funding under the EASTBIO doctoral training programme (grant number 1942576) to AZ and EU Horizon 2020 project FREIA (Grant Number 825100) to PAF. RTM is supported by MRC Centre for Reproductive Health Grant MR/N022556/1.
Competing Interest Statement
Professor David Hay is a founder, director and shareholder in Stemnovate Limited. The remaining authors have no interests to disclose.
Funding Statement
This work is supported by the Biotechnology and Biological Sciences Research council (BBSRC) funding the lead author under the EASTBIO doctoral training programme and to PAF, the EU Horizon 2020 project FREIA (Grant Number 825100). RTM is supported by MRC Centre for Reproductive Health Grant MR/N022556/1. The funders had no role in study design, data collection, data analysis, decision to publish, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AMND dataset used in this study was fully anonymised, therefore there was no requirement for ethical approval. The North of Scotland Research Ethics Service has devolved Caldicott approval to the Chair of the AMND steering committee. Approval to access and analyse data was obtained from the AMND steering Committee (AMND 004/2018).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title, Abstract, Introduction and Discussion text has been revised to increase clarity for the reader.
Data Availability
All data used in this study come from the AMND database. Approval by the Databank Steering Committee is required for access to the data, which has been granted for the purpose of this analysis.
